81 related articles for article (PubMed ID: 23724633)
1. Donor exposures in recipients of pooled platelet concentrates: a case-study in arithmetic, logic, "expert opinion", and the "peer review" process.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(3-4):415-20. PubMed ID: 23724633
[TBL] [Abstract][Full Text] [Related]
2. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
Vamvakas EC
Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
[TBL] [Abstract][Full Text] [Related]
3. Relative risk of reducing the lifetime blood donation deferral for men who have had sex with men versus currently tolerated transfusion risks.
Vamvakas EC
Transfus Med Rev; 2011 Jan; 25(1):47-60. PubMed ID: 21134626
[TBL] [Abstract][Full Text] [Related]
4. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks.
Vamvakas EC
Transfusion; 2009 Dec; 49(12):2743-58. PubMed ID: 19682339
[TBL] [Abstract][Full Text] [Related]
5. Consistency and proportionality in policy decision-making in blood safety: the case for an all-apheresis platelet supply in Germany.
Vamvakas EC; Hitzler WE
Clin Lab; 2013; 59(1-2):1-22. PubMed ID: 23505902
[TBL] [Abstract][Full Text] [Related]
6. Transmission of West Nile virus through blood transfusion in the United States in 2002.
Pealer LN; Marfin AA; Petersen LR; Lanciotti RS; Page PL; Stramer SL; Stobierski MG; Signs K; Newman B; Kapoor H; Goodman JL; Chamberland ME;
N Engl J Med; 2003 Sep; 349(13):1236-45. PubMed ID: 14500806
[TBL] [Abstract][Full Text] [Related]
7. Donor exposures in recipients of pooled platelet concentrates.
Thiele T; Heddle N; Greinacher A
N Engl J Med; 2013 Jan; 368(5):487-9. PubMed ID: 23363522
[No Abstract] [Full Text] [Related]
8. Risk-reduction strategies for platelet transfusion in the United States.
Vamvakas EC
ScientificWorldJournal; 2011 Mar; 11():624-40. PubMed ID: 21403979
[TBL] [Abstract][Full Text] [Related]
9. The RADAR repository: a resource for studies of infectious agents and their transmissibility by transfusion.
Kleinman SH; Glynn SA; Higgins MJ; Triulzi DJ; Smith JW; Nass CC; Garratty G; Murphy EL; LeParc GF; Schreiber GB; King MR; Chamberland ME; Nemo GJ
Transfusion; 2005 Jul; 45(7):1073-83. PubMed ID: 15987350
[TBL] [Abstract][Full Text] [Related]
10. New technologies for the inactivation of infectious pathogens in cellular blood components and the development of platelet substitutes.
Corash L
Baillieres Best Pract Res Clin Haematol; 2000 Dec; 13(4):549-63. PubMed ID: 11102276
[TBL] [Abstract][Full Text] [Related]
11. Pathogen reduction of blood components.
Solheim BG
Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
[TBL] [Abstract][Full Text] [Related]
12. Transmission of West Nile virus from an organ donor to four transplant recipients.
Iwamoto M; Jernigan DB; Guasch A; Trepka MJ; Blackmore CG; Hellinger WC; Pham SM; Zaki S; Lanciotti RS; Lance-Parker SE; DiazGranados CA; Winquist AG; Perlino CA; Wiersma S; Hillyer KL; Goodman JL; Marfin AA; Chamberland ME; Petersen LR;
N Engl J Med; 2003 May; 348(22):2196-203. PubMed ID: 12773646
[TBL] [Abstract][Full Text] [Related]
13. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
Josephson CD; Castillejo MI; Grima K; Hillyer CD
Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
[TBL] [Abstract][Full Text] [Related]
14. Pooled platelet concentrates: an alternative to single donor apheresis platelets?
Pietersz RN
Transfus Apher Sci; 2009 Oct; 41(2):115-9. PubMed ID: 19716340
[TBL] [Abstract][Full Text] [Related]
15. The use of PEG-rhuMGDF in platelet apheresis.
Kuter DJ
Stem Cells; 1998; 16 Suppl 2():231-42. PubMed ID: 11012195
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the impact of public health notification of suspected transfusion-transmissible hepatitis C virus infection and effectiveness of lookback and traceback investigations by Canadian Blood Services in British Columbia, Canada, August 2002 through February 2005.
Whitlock M; Lord S; Buxton JA; Doyle P; Bigham M
Transfusion; 2007 Aug; 47(8):1534-9. PubMed ID: 17655599
[TBL] [Abstract][Full Text] [Related]
17. A program to limit donor exposures to neonates undergoing extracorporeal membrane oxygenation.
Rosenberg EM; Chambers LA; Gunter JM; Good JA
Pediatrics; 1994 Sep; 94(3):341-6. PubMed ID: 8065860
[TBL] [Abstract][Full Text] [Related]
18. Current status of leukocyte and platelet administration in cancer therapy.
Walker EM; Cannon A; Mitchum EN
Ann Clin Lab Sci; 1983; 13(6):453-73. PubMed ID: 6197928
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of multiple donor exposure blood recipients: surveillance value and limitations for hemovigilance.
Zou S; Wu Y; Cable R; Dorsey K; Tang Y; Hapip CA; Melmed R; Trouern-Trend J; Carrano D; Champion M; Fujii K; Fang C; Dodd R
Transfusion; 2010 Jan; 50(1):128-38. PubMed ID: 19778336
[TBL] [Abstract][Full Text] [Related]
20. Platelet crossmatch testing for donor selection.
Slichter SJ
Prog Clin Biol Res; 1982; 88():153-64. PubMed ID: 7100207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
